The first clinically approved therapeutic employing a receptor mediated transcytosis BBB shuttle, pabinafusp alfa, consists of a TfR-binding monoclonal antibody fused to the enzyme iduronate-2-sulfatase, which is defective in mucopolysaccharidosis type II (Hunter syndrome) [6, 7]. Here, TFRC is linked to mucopolysaccharidosis type 2.